Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind.
Saved in:
| Title: | Lenvatinib and Pembrolizumab Move the Needle for Most Non–clear-cell Renal Cell Carcinomas, Yet Rare Histologies Still Lag Behind. |
|---|---|
| Authors: | Dizman, Nazli1 (AUTHOR) ndizman@mdanderson.org, Ebrahimi, Hedyeh2 (AUTHOR), Chehrazi-Raffle, Alexander3 (AUTHOR) |
| Source: | European Urology. Dec2025, Vol. 88 Issue 6, p625-627. 3p. |
| Database: | Academic Search Ultimate |
| ISSN: | 03022838 |
|---|---|
| DOI: | 10.1016/j.eururo.2025.08.009 |
